Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan Combined With Envafolimab in Advanced Biliary Tract Cancers
NCT07729033Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and envafolimab in biliary tract cancer (BTC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate at 1 year. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecanenvafolimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07729033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07729033.